Evidence map›Paper›PMID 39215182›Full record

ArticleLab animal2024

Production of a heterozygous exon skipping model of common marmosets using gene-editing technology.

Kenya Sato, Hiroki Sasaguri, Wakako Kumita, Tetsushi Sakuma, Tomoe Morioka, Kenichi Nagata, Takashi Inoue, Yoko Kurotaki, Naomi Mihira, Michihira Tagami and 7 more

Abstract read
In one paragraph

Article in Lab animal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kenya Sato *Department of Marmoset Biology and Medicine, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan.
Hiroki Sasaguri *Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.ORCID 0000-0003-2550-9156
Wakako KumitaDepartment of Marmoset Biology and Medicine, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan.
Tetsushi SakumaGraduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima, Japan.ORCID 0000-0003-0396-1563
Tomoe MoriokaDepartment of Marmoset Biology and Medicine, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan.
Kenichi NagataDepartment of Functional Anatomy and Neuroscience, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takashi InoueDepartment of Marmoset Biology and Medicine, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan.
Yoko KurotakiCenter of Basic Technology in Marmoset, Central Institute for Experimental Animals, Kawasaki, Japan.
Naomi MihiraLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.
Michihira TagamiLaboratory for Comprehensive Genomic Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Ri-Ichiroh ManabeLaboratory for Comprehensive Genomic Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Kokoro OzakiLaboratory for Comprehensive Genomic Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID 0000-0001-9081-8348
Yasushi OkazakiLaboratory for Comprehensive Genomic Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Takashi YamamotoGraduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima, Japan.
Makoto SuematsuDepartment of Marmoset Biology and Medicine, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan.
Takaomi C SaidoLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan. takaomi.saido@riken.jp.ORCID 0000-0003-1970-6903
Erika SasakiDepartment of Marmoset Biology and Medicine, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan. esasaki@ciea.or.jp.ORCID 0000-0002-0415-5400

Funding

Japan Agency for Medical Research and Development (AMED) 24zf0127007h0003Japan Agency for Medical Research and Development (AMED) JP20dm0207001Japan Agency for Medical Research and Development (AMED) JP20dm0207065MEXT | Japan Society for the Promotion of Science (JSPS) JP21H04756
6 · The paper itself

Abstract

Nonhuman primates (NHPs), which are closely related to humans, are useful in biomedical research, and an increasing number of NHP disease models have been reported using gene editing. However, many disease-related genes cause perinatal death when manipulated homozygously by gene editing. In addition, NHP resources, which are limited, should be efficiently used. Here, to address these issues, we developed a method of introducing heterozygous genetic modifications into common marmosets by combining Platinum transcription activator-like effector nuclease (TALEN) and a gene-editing strategy in oocytes. We succeeded in introducing the heterozygous exon 9 deletion mutation in the presenilin 1 gene, which causes familial Alzheimer's disease in humans, using this technology. As a result, we obtained animals with the expected genotypes and confirmed several Alzheimer's disease-related biochemical changes. This study suggests that highly efficient heterozygosity-oriented gene editing is possible using TALEN and oocytes and is an effective method for producing genetically modified animals.

Indexed as

CallithrixExonsGene EditingHeterozygotePresenilin-1Transcription Activator-Like Effector NucleasesAlzheimer DiseaseAnimalsAnimals, Genetically ModifiedDisease Models, AnimalFemaleOocytesPresenilin-1Transcription Activator-Like Effector Nucleases

Identifiers

PMID39215182
PMCPMC11368816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.